Mast Cells in Human Cutaneous Neurofibromas: Density, Subtypes, and Association with Clinical Features in Neurofibromatosis 1.


Journal

Dermatology (Basel, Switzerland)
ISSN: 1421-9832
Titre abrégé: Dermatology
Pays: Switzerland
ID NLM: 9203244

Informations de publication

Date de publication:
2022
Historique:
received: 11 03 2021
accepted: 24 04 2021
pubmed: 9 7 2021
medline: 15 3 2022
entrez: 8 7 2021
Statut: ppublish

Résumé

Cutaneous neurofibromas (cNFs) are hallmarks of neurofibromatosis 1 (NF1) and cause the main disease burden in adults with NF1. Mast cells are a known component of cNFs. However, no comprehensive characterization of mast cells in cNFs is available, and their contributions to cNF growth and symptoms such as itch are not known. We collected 60 cNFs from ten individuals with NF1, studied their mast cell proteinase content, and compared the mast cell numbers to selected clinical features of the tumors and patients. The tumors were immunolabeled for the mast cell markers CD117, tryptase, and chymase, and the percentage of immunopositive cells was determined using computer-assisted methods. The median proportions of positive cells were 5.5% (range 0.1-14.4) for CD117, 4.0% (1.2-7.0) for tryptase, and 5.0% (1.1-15.9) for chymase. The median densities of cells immunopositive for CD117, tryptase, and chymase were 280, 243, and 250 cells/mm2, respectively. Small tumors, growing tumors, and tumors from patients below the median age of 33 years displayed a high proportion of mast cells. Cells expressing both tryptase and chymase were the predominant mast cell type in cNFs, followed by cells expressing chymase only. The results highlight the abundance of mast cells in cNFs and that their number and subtypes clearly differ from those previously reported in unaffected skin.

Sections du résumé

BACKGROUND BACKGROUND
Cutaneous neurofibromas (cNFs) are hallmarks of neurofibromatosis 1 (NF1) and cause the main disease burden in adults with NF1. Mast cells are a known component of cNFs. However, no comprehensive characterization of mast cells in cNFs is available, and their contributions to cNF growth and symptoms such as itch are not known.
METHODS METHODS
We collected 60 cNFs from ten individuals with NF1, studied their mast cell proteinase content, and compared the mast cell numbers to selected clinical features of the tumors and patients. The tumors were immunolabeled for the mast cell markers CD117, tryptase, and chymase, and the percentage of immunopositive cells was determined using computer-assisted methods.
RESULTS RESULTS
The median proportions of positive cells were 5.5% (range 0.1-14.4) for CD117, 4.0% (1.2-7.0) for tryptase, and 5.0% (1.1-15.9) for chymase. The median densities of cells immunopositive for CD117, tryptase, and chymase were 280, 243, and 250 cells/mm2, respectively. Small tumors, growing tumors, and tumors from patients below the median age of 33 years displayed a high proportion of mast cells. Cells expressing both tryptase and chymase were the predominant mast cell type in cNFs, followed by cells expressing chymase only.
CONCLUSION CONCLUSIONS
The results highlight the abundance of mast cells in cNFs and that their number and subtypes clearly differ from those previously reported in unaffected skin.

Identifiants

pubmed: 34237737
pii: 000517011
doi: 10.1159/000517011
doi:

Substances chimiques

Chymases EC 3.4.21.39
Tryptases EC 3.4.21.59

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

329-339

Informations de copyright

© 2021 The Author(s). Published by S. Karger AG, Basel.

Auteurs

Roope A Kallionpää (RA)

Institute of Biomedicine, University of Turku, Turku, Finland, rookal@utu.fi.

Kaisa Ahramo (K)

Institute of Biomedicine, University of Turku, Turku, Finland.

Eija Martikkala (E)

Institute of Biomedicine, University of Turku, Turku, Finland.

Elnaz Fazeli (E)

Institute of Biomedicine, University of Turku, Turku, Finland.

Pekka Haapaniemi (P)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.

Anne Rokka (A)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.

Ilmo Leivo (I)

Institute of Biomedicine, University of Turku, Turku, Finland.
Department of Pathology, Turku University Hospital, Turku, Finland.

Ilkka T Harvima (IT)

Department of Dermatology, Kuopio University Hospital and University of Eastern Finland, Kuopio, Finland.

Juha Peltonen (J)

Institute of Biomedicine, University of Turku, Turku, Finland.

Sirkku Peltonen (S)

Department of Dermatology and Venereology, University of Turku, Turku, Finland.
Department of Dermatology, Turku University Hospital, Turku, Finland.
Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Dermatology and Venereology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH